Online inquiry

IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7496MR)

This product GTTS-WQ7496MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TGFB1&TGFB2&TGFB3 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000660.7; NM_001135599.4; NM_001329938.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7040; 7042; 7043
UniProt ID P01137; P61812; P10600
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ7496MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9944MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA KB-004
GTTS-WQ3632MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ5844MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ8520MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Hu3F8
GTTS-WQ13234MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-05082566
GTTS-WQ5389MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ5839MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ9714MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64407564
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW